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Background. The use of a squalene-containing (AS03) pandemic vaccine for high-risk groups in England
allowed vaccine effectiveness (VE) of such novel oil-in-water adjuvanted vaccine to be evaluated.
Methods. Cases of laboratory-conﬁrmed pandemic (H1N1)2009 inﬂuenza in England between November
2009 and January 2010 were followed up for history of pandemic (H1N1)2009 or 2009/10 seasonal inﬂuenza
vaccination and relevant comorbidities. Controls were patients similarly tested but negative for the virus. We
estimated pandemic (H1N1)2009 VE from the relative reduction in the odds of conﬁrmed pandemic (H1N1)2009
infection between vaccinated and unvaccinated individuals after adjustment for confounders.
Results. A total of 933 cases and 1220 controls were analyzed. VE from >14 days was 62% (95% CI 33% to
78%) with protection from 7 to 13 days post-vaccination (59%, 95% CI 12% to 81%). VE from >14 days differed by
age (P5.03) being 77% (11% to 94%) in children ,10 years, 100% (80% to 100%) in 10–24-year olds, 22% (-153%
to 76%) in 25–49-year olds, and 41% (-71% to 80%) in 50-plus-year-olds.
Conclusion. Use of oil-in-water adjuvant contributed to a high VE with reduced antigen dosage
in children and young adults. Our VE estimate supports the serological correlates of protection used for
licensure in these age groups. However, the immunological basis of disappointing VE in older adults merits
investigation.
A key element of the global response to an inﬂuenza
pandemic is the rapid development, licensure, and de-
ployment of monovalent pandemic strain vaccines [1].
Before the emergence of pandemic (H1N1) 2009 virus
in April 2009, the most likely pandemic virus candidate
was considered to be avian inﬂuenza H5N1, to which
the population would likely be immunologically naı ¨ve
[2]. To ensure a good antibody response to an H5N1
vaccine and to reduce the amount of antigen needed to
prime theimmune system, the strategy adoptedbysome
manufacturerswastoenhanceimmunogenicitybyusing
novel adjuvants such as an oil-in-water emulsion [3].
However, the emergence of an H1N1 pandemic strain
virus, to which preexisting, cross-reactive antibody
could be demonstrated in many older individuals [4],
suggested that conventional unadjuvanted vaccines may
have been adequate for immunizing against this H1N1
pandemic-strain virus.
As part of its pandemic planning, the United Kingdom
(UK) contracted with two manufacturers to supply
monovalent pandemic-strain vaccine for the UK pop-
ulation. One vaccine was a split-virion vaccine grown in
e g g sa n da d j u v a n t e dw i t hA S O 3, an oil-in-water adjuvant
containing squalene [5]. The other was a whole-cell,
unadjuvanted vaccine grown in Vero cells [6]. Both
vaccines werelicensedbytheEuropeanMedicines Agency
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a similar mock up vaccine containing an H5N1 strain. The use of
a mock-up dossier for a novel inﬂuenza strain allowed a fast track
approach to licensure by obviating the need to generate safety and
immunogenicity data for the actual pandemic strain vaccine [7].
The UK pandemic vaccination program was initially targeted
atindividualsinclinicalriskgroupsforwhomseasonalinﬂuenza
vaccine was alreadyrecommended,withtheadditionalinclusion
of otherwise healthy pregnant women [8]. Subsequently the
vaccination program was extended to healthy children aged 6
months to 5 years [9]. The majority of the vaccine used in
the UK was the ASO3 adjuvanted vaccine. But the use of
the unadjuvanted whole-cell vaccine was restricted to those
with a history of egg allergy and pregnant women preferring
a thiomersal-free vaccine.
We report the effectiveness of the ASO3 adjuvant pandemic
(H1N1) 2009 vaccine in preventing pandemic (H1N1) 2009
disease conﬁrmed in patients who had underlying medical
conditions and were therefore in high-risk priority groups tar-
geted for vaccination in the UK. Protection against hospital
admission as well as less serious disease not requiring hospital-
ization was assessed. We used an established case control
method in which cases are those with laboratory-conﬁrmed
infection and controls are test-negative patients similarly in-
vestigated for suspected infection [10].
METHODS
Study Population
Cases and controls were individuals presenting to health care
services in England with suspected inﬂuenza who had a re-
spiratory swab tested for pandemic (H1N1) 2009 infection
between 9 November 2009 and 4 January 2010. Only those
with disease onset after 1 November 2009 were retained be-
cause this was the earliest date at which any vaccinated patient
could have derived protection. During this period, diagnostic
testing for suspected pandemic (H1N1) 2009 infection was
restricted to patients hospitalized with an inﬂuenza-like ill-
ness or patients presenting in primary care with an inﬂuenza-
like illness who were also in clinical risk groups for which
seasonal vaccine was recommended [11]. A case was deﬁned
as a patient with laboratory-conﬁrmed pandemic (H1N1)
2009 infection in the study period. A control was a patient in-
vestigated during this period but with a negative laboratory test.
In the ﬁrst week of the study, for those swabbed from 9 No-
vember 2009 to 15 November 2009, we sought information on
all cases and controls. After this, to reduce workload, controls
were frequency-matched one-to-one by age group, week sample
was taken, and English region of residence. A questionnaire was
sent to each patient’s general practitioner (GP) for both cases
and controls. This questionnaire requested information on date
of symptom onset, whether or not the person was in a clinical
risk group for inﬂuenza vaccination,and, ifso,whichone. Italso
asked for hospital admission history as well as dates and batch
numbers of any pandemic (H1N1) 2009 or 2009/10 seasonal
trivalent inﬂuenza vaccine doses given.
Laboratory Confirmation
We performed laboratory conﬁrmation of pandemic (H1N1)
2009 virus by using respiratory swabs collected into virus
transport medium. All samples were tested by an HPA Regional
Microbiology Network (RMN) laboratory using real-time re-
verse transcriptase polymerase chain reaction (RT-PCR) assays
for detection of inﬂuenza A and sub-typed for pandemic
(H1N1) 2009 viruses [12, 13]. RMN laboratories followed the
HPA National Standard Method RT-PCR testing protocol and
reported test results weekly to the HPA Centre for Infections.
The sensitivity of the RT-PCR method was 4–40 plaque forming
units detectable per mL [J Ellis personal communication].
Vaccination Programme and Schedule
Starting in the last week of October 2009, vaccine was offered
to heath care workers. Beginning in early November vaccine
was offered to those in clinical risk groups and household
contacts of immunosuppressed patients. It was offered to
healthy children aged under 5 years from early January 2010.
Children aged 6 months to 10 years of age were recommended
to receive a single 0.25 mL dose of the AS03 adjuvanted
vaccine (Pandemrix, Glaxo Smith Kline Vaccines, Rixensart,
Belgium) manufactured from the A/California/7/2009
(H1N1) v-like strain antigen (New York Medical College
x-179A). This vaccine contained 1.875 lg of hemagglutinin
antigen, the oil-in-water emulsion based adjuvant AS03
(containing squalene (5.345mg), DL-a-tocopherol (5.93 mg),
and polysorbate 80 (2.43mg), and thiomersal [9]. Individuals
aged 10-plus years were recommended to receive a 0.5 mL
dose of the same vaccine. A 2- dose schedule was recom-
mended for individuals who were immunocompromised.
Sample-size Calculation
To obtain reasonable precision (6 20%) for a VE of about 70%
approximately 1200 cases and controls were required, assuming
5% of controls were vaccinated.
Statistical Analysis
Multi-variable logistic regression was used to determine the
association between vaccination and conﬁrmed pandemic
(H1N1) 2009 infection. A full model was developed that in-
cluded all clinical risk factors for which the odds ratio of being
a case was signiﬁcantly different from one as well as pandemic
(H1N1) 2009 and seasonal vaccine, age, time period (in weeks),
pregnancy and gender. For estimation of the effectiveness of
pandemic (H1N1) 2009 vaccine with maximum power, only
signiﬁcant variables that changed the odds ratio for the pan-
demic (H1N1) 2009 vaccine effect by 5% or more were retained
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variables were constructed as 4-level variables with unvaccinated
as the baseline, vaccination within 6 days of onset as a period in
which no protective effect is expected (results not shown),
vaccination 7 to 13 days before onset, and vaccination 14 or
moredaysbefore onset. The 6–13daysand14or more day levels
were also combined to give estimates of effectiveness from 7
days. The adjusted odds ratio for a given level such as >14 days
was used to calculate the vaccine effectiveness (VE) for that
level using the formula (1- adjusted odds ratio)*100. The anal-
yses were also performed stratiﬁed by age (,10, 10–24, 25–49,
and 501 years), hospitalized/not hospitalized and also
according to whether the patient was immunosuppressed by
disease or treatment. Finally VE was estimated by age (,25 and
> 25 years) and by immunosuppressive status within the hos-
pitalized patients. Signiﬁcance was taken at a 5% level. Ana-
lysis was performed using STATA software [StataCorp. 2007.
Stata Statistical Software: Release 10. College Station, TX:
StataCorp LP].
Ethical Permission
Informed consent for follow up was not sought from patients.
The work was carried out under NHS Act 2006 (section 251),
which provides statutory support for disclosure of such data by
the NHS, and its processing by the Health Protection Agency for
purposes of communicable disease control.
RESULTS
Descriptive
By 8 March 2010 a total of 4452 questionnaires (from 1905 cases
and 2547 controls) had been returned by GPs in England of the
5942 sent out (74.9% response rate). Of the 4452 patients, 1976
were excluded because they had no underlying chronic con-
ditions and were therefore not eligible for vaccination, although
3 (all controls) were reported to have received vaccine > 14 days
after disease onset. In addition, we excluded 299 individuals
whose onset was before 1 November 2009 (week 45), considered
the earliest date at which any vaccinated patient could have had
protection from pandemic (H1N1) 2009 vaccine. Thirteen cases
and10controlswhohadaswabtaken>30daysafteronsetwere
also excluded. Finally, because only one individual received the
unadjuvanted, whole-cell vaccine, this case was dropped so that
all effectiveness estimates are for Pandemrix. The study pop-
ulation for the analysis of vaccine effectiveness was therefore
restricted to 933 cases, with a conﬁrmed infection with pan-
demic (H1N1) 2009 virus (Table 1) and 1220 controls—all with
chronic conditions that made them eligible for vaccination.
Most cases and controls were young adults and children
(Table 1). The proportions admitted to hospital by age were
similar in cases and controls: 80%, and 81% respectively among
children aged 0–9 years of age, 71% and 65% among 10–24 year
olds, 79% and 67% among 25–49 year olds and 90% and 76%
among 501 year olds. Pregnancy was reported more often in
cases than in controls. Inﬂuenza onset date was known more
often for cases than for controls. Where known, the median
interval from onset to swab was 3 days, with 89% of swabs taken
within 7 days for cases and 85% within 7 days for controls. For
those individuals without a reported onset date, we used the
hospitalization date or date the swab was taken minus 3 days
(the median interval from onset to swab). Inclusion of all con-
trols at the start of the study, followed by age/period/region
matching, led to relatively more controls at the start and also
more controls in the older age groups and children younger
than 5 years. Therefore, it was necessary to adjust for age and
period in our analysis. The vaccine was introduced just after the
peak of the second pandemic wave (Figure 1). This meant many
cases and controls in the study had onset close to the time of
vaccination. Figure 1 also shows that the proportion of PCR-
negative individuals (controls) who were vaccinated followed
the coverage in risk groups in the population as assessed by
a national survey [14].
A total of 31 cases and 76 controls had received at least 1 dose
of pandemic (H1N1) 2009 vaccine >7 days before the onset
date. Of these, no cases and 7 controls had received 2 doses > 7
daysbefore; 6ofthese 7 were reportedtobeimmunosuppressed.
This gives a crude 2-dose vaccine effectiveness (VE) from >7
days of 100% (95% CI 32% to 100%). Because of the small
numbers, we dropped from our multivariable analysis those
individuals receiving 2 doses.
Logistic Regression Modeling Results
In the full multivariable model there was an increased odds of
being a case if pregnant (odds ratio 2.85, 95% CI 1.81 to 4.49)
and a nonsigniﬁcant increase if given seasonal inﬂuenza vaccine
(odds ratio 1.29, 95% CI .99 to 1.68). The odds were decreased
for those with chronic respiratory disease (odds ratio 0.66, 95%
CI0.50 to0.90),thoseimmunosuppressedbydisease(oddsratio
0.62, 95% CI 0.46 to 0.83), and those immunosuppressed by
treatment (odds ratio 0.66, 95% CI 0.50–0.88). In this full-
model pandemic, (H1N1) 2009 vaccine showed a protective
effect with an effectiveness estimate of 60% (95% CI 27% to
78%) from >14 days after vaccination (Table 2).
In the simpler model where variables were dropped if non-
signiﬁcant, or did not confound the pandemic (H1N1) 2009
vaccine effect, only period and age were retained. In this model
the pandemic (H1N1) 2009 VE from > 14 days post-
vaccination was 62% (95% CI 33% to 78%), Table 2. Within the
7–13 day post-vaccination period a signiﬁcant protective effect
was also found with VE 5 59% (95% CI 12% to 81%). When
this period was combined with the >14 day period the VE from
>7 days post-vaccination was 61% (95% CI 38% to 75%).
Our sub-analyses showed evidence that VE differed by age
(P 5 .03) for the age-vaccine interaction. To increase precision,
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Variable
No. of cases
(Total 5933) %
No. of controls
(Total51220) %
Received pandemic vaccine
1
st dose >14 days before estimated onset 21 2.3 45 3.7
1
st dose 7–13 days before estimated onset 10 1.1 24 2.0
1
st dose ,7 days before estimated onset 39 4.2 39 3.2
2
nd dose >14 days before estimated onset 0 0.0 5 0.4
2
nd dose 7–13 days before estimated onset 0 0.0 2 0.2
Unvaccinated 756 81.0 938 76.9
Vaccination status unknown 107 11.5 167 13.7
Received seasonal vaccine
Vaccinated >14 days before Estimated onset 220 23.6 294 24.1
Vaccinated 7–13 days before estimated onset 24 2.6 35 2.9
Vaccinated ,7 days before estimated onset 18 1.9 34 2.8
Unvaccinated 559 59.9 696 57.1
Vaccination status unknown 112 12.0 161 13.2
Sex and Pregnancy
Female – not pregnant 396 42.4 533 43.7
Female – pregnant 130 13.9 53 4.3
Female – pregnant unknown 4 0.4 15 1.2
Male 403 43.2 619 50.7
Age group (years)
,5 123 13.2 203 16.6
5–9 110 11.8 126 10.3
10–14 85 9.1 66 5.4
15–24 120 12.9 135 11.1
25–34 146 15.7 130 10.7
35–49 152 16.3 198 16.2
50–64 146 15.7 216 17.7
651 51 5.5 146 12.0
Interval (days between onset and sample collection)
0–1 220 23.6 204 16.7
2–4 268 28.7 199 16.3
5–7 102 10.9 88 7.2
8–14 53 5.7 69 5.7
15–29 17 1.8 19 1.6
Not stated, interval estimated from date of swab or hospitalization 273 29.3 641 52.5
Hospitalized
No 159 17.0 263 21.6
Yes 669 71.7 728 59.7
Unknown 105 11.3 229 18.8
Risk factor
a
Chronic respiratory 151 16.2 272 22.3
Chronic heart 98 10.5 179 14.7
Chronic renal 64 6.9 112 9.2
Chronic liver 30 3.2 55 4.5
Chronic neurological 120 13.3 162 12.9
Diabetes 100 10.7 138 11.3
Immunosuppressant disease 118 12.7 259 21.2
Immunosuppressant treatment 139 14.9 268 22.0
Any asthma 403 43.2 429 35.1
Severe asthma 242 25.9 259 21.2
NOTE. If symptom onset date was not stated, onset date is presume to be date of hospitalization or 3 days before date of swab was taken.
a Note that individuals may have multiple risk factors.
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from > 7 days post vaccination was 73% (44% to 87%) in those
aged ,25 years compared to 50% (6% to 74%) in those aged
251 years. VE from > 14 days post-vaccination was 89% (66%
to96%) inthoseaged,25comparedto27%(254%to65%) in
those aged 251 years. There were no signiﬁcant interactions
between vaccine and hospitalization (P 5 .29) or vaccine and
immunosuppressant disease/therapy (P5 .11).
In analyses restricted to hospitalized patients (Table 3) VE
from 14 days was higher in those without immunosuppression
(P 5 .02) and in those aged ,25 (P5.02). Among those
without immunosuppression, VE was 89% (47% to 98%) for
,25 and 213% (2303% to 68%) for > 25 year olds, similar to
the overall estimates by age.
DISCUSSION
Our study has shown that the pandemic (H1N1) 2009 strain
split virion AS03 adjuvanted vaccine protects against pan-
demic (H1N1) 2009 infection in the high-risk groups targeted
for immunization in the UK with signiﬁcant protection (61%,
95% CI 38% to 75%) demonstrated from as early as 7 days
after vaccination. For children younger than 10 years, as
permitted under the licensed indication, the UK recom-
mended a single 0.25 mL dose based on concerns about the
high proportion with fever after a second 0.25 mL dose in
a small manufacturer- sponsored study [5]. The effectiveness
estimate for this age group from 14 days after vaccination was
7 7 %( 9 5%C I1 1 %t o9 4 % ) .T h i sc o m p a r e sw i t haC o c h r a n e
Table 2. Adjusted Vaccine Effectiveness (VE) Estimates for a Single Dose of AS03 Adjuvanted Pandemic (H1N1) 2009 Vaccine by Age
Group, Risk Group and Whether Admitted to Hospital
Analysis (No. of Observations)
VE (95% CI)
Onset > 7 days since vaccination Onset > 14 days since vaccination
Full model (1758)
a 60% (33% to 75%) 60% (27% to 78%)
Simple model (1872)
b 61% (38% to 75%) 62% (33% to 78%)
Risk group
Immunosuppressant disease/therapy
b (504) 29% (-53% to 67%) 33% (-76% to 75%)
Others (1368) 68% (41% to 82%) 65% (29% to 83%)
Age group
b
0–9 (502) 37% (-50% to 74%) 77% (11% to 94%)
10–24 (351) 100% (85% to 100%)
c 100% (80% to 100%)
c
25–49 (527) 61% (-9% to 86%) 22% (-153% to 76%)
501 (492) 52% (-18% to 80%) 41% (-71% to 80%)
Hospitalized
b
No (383) 52% (-47% to 84%) 68% (-60% to 94%)
Yes (1246) 45% (3% to 69%) 42% (-14% to 70%)
NOTE.
aAdjusting for age, period, sex, pregnancy, seasonal vaccine, immunosuppressant disease, immunosuppressant treatment, and chronic respiratory
disease.
b Adjusting for age and period only.
c No cases exposed, so unadjusted exact 95% CI calculated.
Table 3. Vaccine Effectiveness (VE) Estimates for a Single Dose of AS03 Adjuvanted Pandemic (H1N1) 2009 Vaccine by Age Group and
Risk Group in Hospitalized Patients
Analysis (No. of Observations)
VE (95% CI)
Onset > 7 days since vaccination Onset > 14 days since vaccination
Full model (1181)
a 52% (12% to 74%) 49% (-4% to 75%)
Simple model (1246)
b 45% (3% to 69%) 42% (-14% to 70%)
Risk group
b
Immunosuppressant disease/therapy (278) 20% (-107% to 69%) -54% (-463% to 52%)
Others (968) 49% (-6% to 75%) 56% (-1% to 81%)
Age group
b
0–24 (567) 59% (1% to 83%) 80% (32% to 94%)
251 (679) 40% (-30% to 73%) 1% (-156% to 62%)
NOTE.
a Adjusting for age, period, sex, pregnancy, seasonal vaccine, immunosuppressant disease, immunosuppressant treatment, and chronic respiratory
disease.
b Adjusting for age and period only.
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unajuvanted seasonal inﬂuenza vaccines against conﬁrmed
inﬂuenza in healthy children [15]. The high effectiveness we
found in young children was consistent with the limited im-
munogenicity data available for this vaccine. In a small
manufacturer-sponsored study, 99% and 81% of children
aged 6–35 months had a 4-fold rise in titer by hemaggluti-
nation inhibition (HI) or microneutralization assay re-
spectively after a single dose [5]. Although serological
correlates of protection for children have notbeen established,
for the purposes of licensure of pandemic strain vaccine,
correlates established in adults for seasonal inﬂuenza vaccines
were adopted. Our data suggest that these putative serological
correlates predict protection in young children.
In contrast, protection was poor in individuals aged
251 years, with VE only 27% (254% to 65%) in those
aged 251 years from >14 days after vaccination. The VE esti-
mate in 251 year olds compares unfavorably with that of un-
adjuvanted seasonal inﬂuenza vaccine in this age group against
a matched strain. A recent Cochrane systematic review found an
efﬁcacy of 80% (95% CI 56% to 91%) for unadjuvanted, tri-
valent seasonal vaccine against virologically conﬁrmed inﬂuenza
in adults aged 16–64 years,withan efﬁcacy of50%(95%CI27%
to 65%) against an unmatched strain [16]. Unlike these earlier
studies, ours was in individuals with high- risk chronic con-
ditions, many of whom were admitted to a hospital. The high
vaccine effectiveness we found in hospitalized patients under 25
years of age who had chronic conditions suggests that these
factors per se are not the cause of the low effectiveness in older
age groups. Although we did not have enough power to stratify
VE estimates by individual clinical conditions, exclusion of
immunocompromised patients did not alter the age-effect with
theVEestimateamonghospitalizedpatients,89%(47%to98%)
for those aged ,25 years and -13 % (2303% to 68%) for those
aged 251 years.
To date, the immunogenicity data available in adults for the
AS03 adjuvant H5N1 and pandemic (H1N1) 2009 vaccines has
been generated in healthy individuals and has shown at least
95% of those aged 18–60 years seroconverting by HI after
a single 0.5 mL dose of the Pandemic (H1N1) 2009 vaccine with
somewhat lower rates (80%) in those aged 601 years [5].
Patients in our effectiveness study had comorbidities that may
have had a negative impact on their immune response to vac-
cination but removal of those who were immunosuppressed did
not materially affect the VE estimates. Because of their un-
derlyingclinicalconditions,manypatientsinourstudyarelikely
to have had repeated doses of seasonal inﬂuenza vaccine in the
past, because this has been the UK policy for over 20 years.
Recent studies in Canada reported that receipt of 2008/9 in-
ﬂuenza vaccine increased the risk of pandemic (H1N1) 2009
disease [17]. This suggests that prior seasonal inﬂuenza vacci-
nation may have a negative effect on generation of protective
antibody responses to the pandemic (H1N1) 2009 hemaggluti-
nin. In our study, some evidence was found of an increased risk
(odds ratio 1.29,95%CI 0.99 – 1.69) for those who had received
the 2009/10 seasonal inﬂuenza vaccine. We did not collect in-
formation on receipt of previous years’ seasonal vaccine, but it is
likely that since our study was in high-risk groups, receipt of
vaccine in 2009/10 would be a predictor of vaccination in earlier
years.
Figure 1. Distribution by week and year of illness onset and proportion vaccinated for the PCR swab positives and negatives in the vaccine
effectiveness analyses. Also shown is the cumulative pandemic (H1N1) 2009 vaccine coverage in risk groups in England by week of administration, and
estimated distribution of cases* in the second wave by week of onset from week 35, 2009 to week 7, 2010. * Estimated from influenza-like illness reports
from general practice data (Q surveillance) combined with pandemic (H1N1) 2009 positivity rates from routine swabbing of influenza-like illness cases.
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inﬂuenza vaccine on the serological response to subsequent
booster vaccination with a heterologous strain ASO3 adjuvanted
vaccine has been reported for an H5N1 vaccine [18]. In this
study, the HI response to 2 booster doses with ASO3 adjuvanted
A/Indonesia/5/2005) vaccine in individuals primed with un-
adjuvanted H5N1 A/Vietnam/1194/2004 vaccine was signiﬁ-
cantly lower than in un-primed individuals. A negative effect of
prior vaccination withunadjuvantedtrivalentseasonalinﬂuenza
vaccine on the response to an alum-adjuvanted H5N1 vaccine
has also been reported in children under 10 years of age [19]. If
the lower effectiveness of the ASO3 adjuvanted H1N1 vaccine in
adults aged 251 years is associated with a poorer serological
response due to prior receipt of unadjuvanted heterologous A
inﬂuenza strains in seasonal vaccines, then a possible explana-
tion is the original antigenic sin (OAS) hypothesis. In this sit-
uation, new inﬂuenza strains evade surveillancewhenmemoryB
cells reactive to previous strains dominate the serological re-
sponse [20,21]. Such an effect would be more likely in older
individuals with greater cumulative exposure to different in-
ﬂuenza strains. This phenomenon may be the immunological
basis of the reduced response to an adjuvanted heterologous
pandemic strain vaccine seen after priming with an un-
adjuvanted vaccine. It does not seem to occur when un-
adjuvanted, trivalent subunit seasonal vaccines are given
sequentially—at least not to the B inﬂuenza component of such
vaccines [22].
For future pandemic vaccine development it is important to
understand the immunological basis for poor protection with
the ASO3 adjuvanted vaccine in older individuals. For this,
immunogenicity data, including studies of the clonality and
afﬁnity of antibodies produced by the early antibody-secreting
plasma cells and later memory B cells, would allow hypotheses
about the immunological basis of poor protection from the
adjuvanted H1N1 pandemic vaccine to be tested.
Ourswasanobservationalstudy,notarandomisedcontrolled
trial. Therefore it is subject to bias. However, the test-negative
design we employed has been used to estimate inﬂuenza vaccine
effectiveness in a number of studies with robust and plausible
results [10,16, 23,24, 25]. Our study’s strengthis thatbothcases
and controls have presented with an inﬂuenza-like illness, and
their true status is unknown at the time of swabbing. Lack of
PCR assay sensitivity could lead to underestimation of effec-
tiveness, because cases are classiﬁed as controls. This seems
unlikely, however, because the HPA RT-PCR is highly sensitive,
most samples were taken within 7 days, and we saw a high VE
estimateof89% from> 14dayswasobtainedinthose aged,25
years. Collection of information on comorbidities and preg-
nancy enabled adjustment for these factors. However, with the
exception of pregnancy, other clinical conditions were no more
common among cases than controls. A retrospective collection
ofvaccinationhistoryhasthe potentialtointroduce biasbecause
it is done after the result is known. However, our study’s vac-
cination status was based on dates of vaccination and batch
numbers recordedinGPnotesrather thanpatientrecall, making
biased reporting less likely.
In conclusion, our study has shown that one dose of AS03
adjuvanted pandemic (H1N1) 2009 vaccine is highly protective
in children and young adults. Its results therefore support the
putative serological correlates of protection used for licensure in
this age group. Effectiveness in adults aged 251 years was,
however, disappointing. This ﬁnding merits further in-
vestigation to understand its immunological basis. It also
highlights the need to conduct immunological studies in high-
risk groups, including those who have had repeated exposure to
unadjuvanted seasonal vaccines, as part of the dossier used to
support licensure of pandemic strain vaccines in the future.
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